Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/19/24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewsWire • 03/06/24
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceGlobeNewsWire • 02/22/24
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's WhyZacks Investment Research • 02/14/24
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep goingZacks Investment Research • 01/26/24
Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi FamiliesSeeking Alpha • 01/23/24
The best-performing stock of the year rose nearly 10-fold, while the second-best averted disaster to surge 1,000% in a wild 2023Market Watch • 12/27/23
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23
Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open-Label Study of DCCR in Prader-Willi SyndromeGlobeNewsWire • 11/06/23
Correcting & Replacing -- Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research SymposiumGlobeNewsWire • 10/04/23
Soleno Therapeutics Announces DCCR Data Presentation at the Foundation for Prader-Willi Research SymposiumGlobeNewsWire • 10/04/23
Meet Soleno Therapeutics, The Company Whose Hunger Suppressant Sent Shares Flying 505%Investors Business Daily • 10/03/23
Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 10/02/23
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded WarrantsGlobeNewsWire • 09/28/23